Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Fauna Bio logo — Animal Genomics for Human Health

Fauna Bio

Animal Genomics for Human Health

Founded 2018 United States Berkeley, United States 22 employees Total: $13.33M Biotechnology, Health Care

General Information

Company Name Fauna Bio
Founded Year 2018
Location United States Berkeley, United States
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Health Care
Business Model B2B, Platform, B2G
Revenue Model Performance Based, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Fauna Bio. To contact Fauna Bio, visit faunabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Fauna Bio compare?

A PDF of Fauna Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Fauna Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Fauna Bio

Fauna Bio, founded in 2018, is a pioneering enterprise at the intersection of Biotechnology and Health Care. The company is headquartered in the United States and operates under the innovative slogan "Animal Genomics for Human Health."

The core of Fauna Bio's mission is to tap into the rich biology of non-model organisms, harnessing their unique mammalian phenotypes to craft novel therapeutics. These solutions aim to prevent diseases and mitigate age-related ailments, with a transformative potential for human health care.

Despite its promising endeavors, details regarding recent investments remain scant, with the last known funding occurring on 01 January 2022 from Planet 9 Capital. This strategic backing underscores investor confidence, although further capital influx could bolster its ambitious research and development roadmap.

Business keywords: Animal Genomics, Human Health, Non-Model Organism Biology, Translational Therapeutics, Disease Prevention, Age-Related Diseases, Heart Disease, Neurodegenerative Disease, Hibernation Mechanisms, Deep-Diving Adaptations, Pre-Clinical Testing, Early Clinical Testing, Disease Mechanism Research, Mammalian Phenotypes

Services & Products

AI platform Convergence™ for drug discovery
Collaborative research agreements
Biological insights from animal models

Target Customers

Pharmaceutical companies Research institutions Biotech investors Space research organizations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Round Undisclosed 1
Planet 9 Capital
01 Jan 2022
Seed $9.00M 7
Vibe Capital True Ventures Pacific 8 Ventures
Vibe Capital, True Ventures +5
01 Sep 2021
Grant Undisclosed 1
National Human Genome Research Institute
National Human Genome Research Institute
01 Mar 2021
Grant $230.00K 1
National Institute of Health
National Institute of Health
01 Oct 2019
Seed $4.10M 2
True Ventures Pacific 8 Ventures
True Ventures, Pacific 8 Ventures
01 Apr 2019
Spinout Undisclosed 2
Broad Institute, Stanford University
01 Jun 2018

Fauna Bio Alternatives & Competitors

View All Alternatives
Fauna Bio vs
Paratus Sciences
Paratus Sciences United States

Translating evolutionary insights into first-in-class medicines

Series A
19 employees
Biotechnology, Health Care
Fauna Bio vs
Engitix Therapeutics
Engitix Therapeutics United Kingdom

Decoding the ECM space to unlock unprecedented therapies for chronic diseases

Series A
65 employees
Biotechnology, Health Care
Fauna Bio vs
NewLimit
NewLimit United States

NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic repr...

Series C
55 employees
Biotechnology, Health Care
View all alternatives

FAQ About Fauna Bio

Animal Genomics for Human Health
Fauna Bio was founded in 2018.
Fauna Bio is headquartered in Berkeley, United States.
Fauna Bio operates in Biotechnology and Health Care. Its work centres on Animal Genomics, Human Health, Non-Model Organism Biology and Translational Therapeutics. Its customers include Pharmaceutical companies, Research institutions and Biotech investors.
Fauna Bio has a B2B, Platform and B2G business model. Its revenue comes from Performance Based, Licensing and Project Based.
Fauna Bio has approximately 22 employees.
Fauna Bio has completed 6 funding rounds, raising a total of $13.33M.
Fauna Bio offers: AI platform Convergence™ for drug discovery, Collaborative research agreements, Biological insights from animal models.
Top alternatives and competitors to Fauna Bio include Paratus Sciences, Engitix Therapeutics, NewLimit, Antiverse, Atomwise. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Fauna Bio and Paratus Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Fauna Bio, https://bouncewatch.com/company/fauna-bio, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes